Testing a new antibody treatment for hard-to-treat lymphoma

Plain-English translation of NCT06021678 on ClinicalTrials.gov ↗ · Source last updated February 2025 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called EX103 to treat a type of blood cancer called non-Hodgkin lymphoma that has come back or stopped responding to earlier treatments. The study will first figure out the safest dose and how well the medication works, then test it in larger groups of patients to confirm it is both safe and effective.

People with lymphoma that returns or resists standard treatments have very few good options left. This trial exists to see if this new antibody-based treatment can help patients who have already tried multiple other therapies without success.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with CD20-positive non-Hodgkin lymphoma that has either returned or stopped responding to treatment
you have already received at least two rounds of prior chemotherapy or cancer treatment
you have at least one measurable tumor that can be seen on a CT or MRI scan
you are willing to receive injections once per week for the first two months, then once every two weeks after that

You likely don't qualify if…

you have a type of non-Hodgkin lymphoma where the CD20 marker disappeared after previous rituximab treatment
you have had fewer than two prior treatment regimens for your lymphoma
you do not have any measurable tumors that can be evaluated by imaging
you are unable or unwilling to commit to the full treatment schedule and follow-up visits

What participation looks like

You would receive injections of the medication—once a week for the first two months, then once every two weeks after that. Each treatment cycle lasts 28 days. You will have regular visits for blood tests, scans to measure your tumors, and check-ups to see how you are responding and whether you are having any side effects.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(4 sites)

China

Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan

Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong

Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine, Shanghai, Shanghai Municipality

Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality